Business
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025
• Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New York February 10th-12th
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"• Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New York February 10th-12th\nWILMINGTON, Del., Feb. 6, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", or the \"Company\"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., (\"HOPE\"), a medical and technology driven company and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. announced today that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals will be presenting a Company update at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11th-12th.\n\n \n \n \n \n \n \n\n \nThe presentation is scheduled for Wednesday, February 12th, from 9:20 – 9:50 AM EST. A live webcast will be accessible on NRX Events, within the Investor Relations section of the Company's website. A replay of the webcast will also be available for 30 days following the event.\nManagement will also be available for one-on-one meetings in New York from February 10th-12th. To schedule meetings in New York or at the BIO CEO & Investor Conference, please contact [email protected].\nAbout NRx Pharmaceuticals\nNRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.\nNRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100...